A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy

OBJECTIVE: In this Phase 2 multicenter study the efficacy and safety of oral abiraterone acetate (1000 mg/once daily) plus prednisolone (5 mg/twice daily) was evaluated in metastatic castration-resistant prostate cancer patients from Japan who had previously received docetaxel-based chemotherapy. ME...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Jpn J Clin Oncol
Главные авторы: Satoh, Takefumi, Uemura, Hiroji, Tanabe, Kazunari, Nishiyama, Tsutomu, Terai, Akito, Yokomizo, Akira, Nakatani, Tatsuya, Imanaka, Keiichiro, Ozono, Seiichiro, Akaza, Hideyuki
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2014
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4243578/
https://ncbi.nlm.nih.gov/pubmed/25425730
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyu148
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы